Advertisement

Clinical and Experimental Nephrology

, Volume 15, Issue 3, pp 410–413 | Cite as

Nephrotic syndrome developing during induction chemotherapy for childhood acute lymphoblastic leukemia

  • Chanel Prestidge
  • Shahrad Rod Rassekh
  • Douglas G. Matsell
Case Report
  • 123 Downloads

Abstract

This report is the first to document minimal change nephrotic syndrome occurring during induction chemotherapy for childhood acute lymphoblastic leukemia (ALL). This occurrence lends further support to the theory of immune cell dysregulation being central to the pathogenesis of nephrotic syndrome in ALL, rather than alternative postulations that this association is due to an increased risk of malignancy secondary to prior immunosuppressive treatment for nephrotic syndrome.

Keywords

Minimal change nephrotic syndrome Acute lymphoblastic leukaemia Malignancy 

Notes

Acknowledgments

We sincerely thank Dr Alex Magil (Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver) for his help with the biopsy slides.

Conflict of interest

All the authors have declared no competing interest.

References

  1. 1.
    Papper S. Nephrotic syndrome and neoplasm. The findings to date, with practical implications. Postgrad Med. 1984;76(147–8):53–8.Google Scholar
  2. 2.
    Dabbs DJ, Striker LM, Mignon F, Striker G. Glomerular lesions in lymphomas and leukemias. Am J Med. 1986;80:63–70.CrossRefGoogle Scholar
  3. 3.
    Ronco PM. Paraneoplastic glomerulopathies: new insights into an old entity. Kidney Int. 1999;56:355–77.CrossRefGoogle Scholar
  4. 4.
    Sinha R, AlAbbas A, Dionne JM, Hurley RM. Simultaneous occurrence of atypical hemolytic uremic syndrome and acute lymphoblastic leukemia: a case report and literature review. Pediatr Nephrol. 2008;23:835–9.CrossRefGoogle Scholar
  5. 5.
    Lee JC, Yamauchi H, Hopper J Jr. The association of cancer and the nephrotic syndrome. Ann Intern Med. 1966;64:41–51.CrossRefGoogle Scholar
  6. 6.
    Da’as N, Polliack A, Cohen Y, Amir G, Darmon D, Kleinman Y, et al. Kidney involvement and renal manifestations in non-Hodgkin’s lymphoma and lymphocytic leukemia: a retrospective study in 700 patients. Eur J Haematol. 2001;67:158–64.CrossRefGoogle Scholar
  7. 7.
    Bhatia M, Kher K, Minniti CP. Acute lymphoblastic leukemia in a child with nephrotic syndrome. Pediatr Nephrol. 2004;19:1290–3.CrossRefGoogle Scholar
  8. 8.
    Kuis W, de Kraker J, Kuijten RH, Donckerwolcke RA, Voute PA. Acute lymphoblastic leukaemia after treatment of nephrotic syndrome with immunosuppressive drugs. Helv Paediatr Acta. 1976;31:91–5.PubMedGoogle Scholar
  9. 9.
    Mackie FE, Roy LP, Stevens M. Onset of leukaemia after levamisole treatment for nephrotic syndrome. Pediatr Nephrol. 1994;8:527–8.CrossRefGoogle Scholar
  10. 10.
    Muller W, Brandis M. Acute leukemia after cytotoxic treatment for nonmalignant disease in childhood. Eur J Pediatr. 1981;136:105–8.CrossRefGoogle Scholar
  11. 11.
    Perard L, Thomas X, Jaumain H, Theuil G, Bret M, Coronel B, et al. T-cell lineage acute lymphoblastic leukemia with chromosome 5 abnormality in a patient with Crohn’s disease and lipoid nephrosis. Ann Hematol. 2000;79:222–5.CrossRefGoogle Scholar
  12. 12.
    Rajpoot D, Tejani A, Rao S, Miller S. Focal segmental glomerulosclerosis in a child with acute lymphoblastic leukemia. Child Nephrol Urol. 1990;10:231–3.PubMedGoogle Scholar
  13. 13.
    Sathiapalan RK, Velez MC, McWhorter ME, Irwin K, Correa H, Baliga R, et al. Focal segmental glomerulosclerosis in children with acute lymphocytic leukemia: case reports and review of literature. J Pediatr Hematol Oncol. 1998;20:482–5.CrossRefGoogle Scholar
  14. 14.
    Fiser RT, Arnold WC, Charlton RK, Steele RW, Childress SH, Shirkey B. T-lymphocyte subsets in nephrotic syndrome. Kidney Int. 1991;40:913–6.CrossRefGoogle Scholar
  15. 15.
    Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet. 1974;2:556–60.CrossRefGoogle Scholar
  16. 16.
    Garin EH. Circulating mediators of proteinuria in idiopathic minimal lesion nephrotic syndrome. Pediatr Nephrol. 2000;14:872–8.CrossRefGoogle Scholar
  17. 17.
    Bakker WW, van Luijk WH. Do circulating factors play a role in the pathogenesis of minimal change nephrotic syndrome? Pediatr Nephrol. 1989;3:341–9.CrossRefGoogle Scholar
  18. 18.
    Gonzalez E, Neuhaus T, Kemper MJ, Girardin E. Proteomic analysis of mononuclear cells of patients with minimal-change nephrotic syndrome of childhood. Nephrol Dial Transplant. 2009;24:149–55.CrossRefGoogle Scholar
  19. 19.
    Sahali D, Pawlak A, Valanciute A, Grimbert P, Lang P, Remy P, et al. A novel approach to investigation of the pathogenesis of active minimal-change nephrotic syndrome using subtracted cDNA library screening. J Am Soc Nephrol. 2002;13:1238–47.PubMedGoogle Scholar
  20. 20.
    Hultin LE, Hausner MA, Hultin PM, Giorgi JV. CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry. 1993;14:196–204.CrossRefGoogle Scholar
  21. 21.
    Kolstad A, Holte H, Fossa A, Lauritzsen GF, Gaustad P, Torfoss D. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica. 2007;92:139–40.CrossRefGoogle Scholar
  22. 22.
    Motto DG, Williams JA, Boxer LA. Rituximab for refractory childhood autoimmune hemolytic anemia. Isr Med Assoc J. 2002;4:1006–8.PubMedGoogle Scholar
  23. 23.
    Sahali D, Pawlak A, Le Gouvello S, Lang P, Valanciute A, Remy P, et al. Transcriptional and post-transcriptional alterations of IkappaBalpha in active minimal-change nephrotic syndrome. J Am Soc Nephrol. 2001;12:1648–58.PubMedGoogle Scholar
  24. 24.
    Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin’s lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res. 2005;65:264–76.PubMedGoogle Scholar
  25. 25.
    Aggarwal N, Batwara R, McCarthy ET, Sharma R, Sharma M, Savin VJ. Serum permeability activity in steroid-resistant minimal change nephrotic syndrome is abolished by treatment of Hodgkin disease. Am J Kidney Dis. 2007;50:826–9.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2011

Authors and Affiliations

  • Chanel Prestidge
    • 1
  • Shahrad Rod Rassekh
    • 2
  • Douglas G. Matsell
    • 1
  1. 1.Division of Nephrology, Department of PediatricsBritish Columbia Children’s HospitalVancouverCanada
  2. 2.Division of Pediatric Haematology/Oncology/BMT, Department of PediatricsBCCHVancouverCanada

Personalised recommendations